SRR25617877
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
- ANGIOGENESIS+0.590
- TNFA_SIGNALING_VIA_NFKB+0.530
- COAGULATION+0.510
- MYOGENESIS+0.450
- UV_RESPONSE_DN+0.450
- APOPTOSIS+0.400
- APICAL_SURFACE+0.380
- KRAS_SIGNALING_UP+0.380
- HYPOXIA+0.370
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.450
- MYC_TARGETS_V1-0.330
- MYC_TARGETS_V2-0.330
- INTERFERON_ALPHA_RESPONSE-0.280
- MITOTIC_SPINDLE-0.270
- OXIDATIVE_PHOSPHORYLATION-0.240
- MTORC1_SIGNALING-0.230
- DNA_REPAIR-0.200
- PROTEIN_SECRETION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.942 |
| 2 | C3L-02552 | — | cohortSQ1 | 0.941 |
| 3 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.924 |
| 4 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.914 |
| 5 | TCGA-56-7731-01A-11R-2125-07 | — | cohortSQ1 | 0.914 |
| 6 | C3N-00545 | — | cohortA1 | 0.904 |
| 7 | TCGA-BH-A0BO-01A-23R-A12D-07 | — | A | 0.904 |
| 8 | SRR8392884 | — | cohortA1 | 0.902 |
| 9 | SAMN03290935 | — | — | 0.901 |
| 10 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.620 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.590 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| COAGULATION | 0.510 | Binimetinib | — uncovered |
| MYOGENESIS | 0.450 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |